1. HBW Insight
  2. >>ESG
  3. >>Diversity & Inclusion

Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says

 
• By Sue Sutter

In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

Diverse hands
The FDA expects studies can be conducted with diversity action plans 'in most cases.' • Source: Shutterstock

[Editor's note: A version of this story appeared first in our sister publication, Pink Sheet.]

The US Food and Drug Administration wants new clinical trial diversity action plans to be short and waiver requests filed early, albeit

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diversity & Inclusion

Bayer Study: Self-Care Is Hardest For Those Who Need It Most

 
• By David Ridley

Being poor makes it more likely that you will suffer from self-treatable health conditions but it also means you will find it harder to take advantage of self-care solutions, finds a recently-published study by Bayer Consumer Health and IQVIA.

Beauty Deserts, People With Disabilities, Hormonal Health: FIT Grads On Inclusivity Gaps

 
• By Ryan Nelson

The Fashion Institute of Technology’s “Beauty Think Tank” provides findings from six months of consumer research to “help guide organizations through the evolving landscape of beauty and accessibility.”

Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says

 
• By Sue Sutter

In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.

Diversity Enrichment: US FDA Guidance Suggests Sponsors May Need To Overenroll Key Groups

 
• By Sarah Karlin-Smith

New draft guidance on clinical trial diversity action plans pushes for disproportionately high enrollment of traditionally underrepresented groups, while also asking companies to tailor global programs to US populations and consider diversity aspects that Congress did not outline. 

More from ESG

AESGP Slams ‘Deeply Concerning And Discriminatory’ EU Wastewater Directive

 
• By David Ridley

“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.

‘We All Have To Start Somewhere’: How Retailers Are Shaping Perrigo’s Climate Ambitions

 
• By David Ridley

Perrigo's retail customers are expecting real "net zero" progress from consumer health manufacturers, which is in turn driving the firm's sustainability ambitions and expectations from their own suppliers, Perrigo’s UK ethical compliance lead Isobel Gay tells HBW Insight in this exclusive interview.

EU Urban Wastewater Directive ‘Highly Disproportionate,’ Says AESGP

 
• By David Ridley

Pharmaceutical industry associations are united in their view that the revised EU Urban Wastewater Treatment Directive discriminates against medicines and cosmetics producers.